Aggresome formation and neurodegenerative diseases: therapeutic implications
about
Alzheimer's disease-associated ubiquilin-1 regulates presenilin-1 accumulation and aggresome formationSUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegansPaired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomesSpatial protein quality control and the evolution of lineage-specific ageingUbiquilin-1 is a molecular chaperone for the amyloid precursor proteinUbiquitin phosphorylation in Parkinson's disease: Implications for pathogenesis and treatmentDirect and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein ToxicityMechanisms for quality control of misfolded transmembrane proteinsParticle-rich cytoplasmic structure (PaCS): identification, natural history, role in cell biology and pathologyProtein Oxidation in Aging: Does It Play a Role in Aging Progression?An intrinsically disordered region of the acetyltransferase p300 with similarity to prion-like domains plays a role in aggregationProtein Aggregates Are Recruited to Aggresome by Histone Deacetylase 6 via Unanchored Ubiquitin C TerminiThe ubiquitin-proteasome system in spongiform degenerative disordersHDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytesRuvbL1 and RuvbL2 enhance aggresome formation and disaggregate amyloid fibrils.Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines.Proteomic characterization of an isolated fraction of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12 cells might offer clues to aggresomes as a cellular defensive response against proteasome inhibition by PSI.Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes.Proteasome failure promotes positioning of lysosomes around the aggresome via local block of microtubule-dependent transport.Formation and toxicity of soluble polyglutamine oligomers in living cells.Distribution of activator of G-protein signaling 3 within the aggresomal pathway: role of specific residues in the tetratricopeptide repeat domain and differential regulation by the AGS3 binding partners Gi(alpha) and mammalian inscuteable.Lactic acid induces aberrant amyloid precursor protein processing by promoting its interaction with endoplasmic reticulum chaperone proteins.Aggresome formation is regulated by RanBPM through an interaction with HDAC6Parkin-mediated ubiquitin signalling in aggresome formation and autophagy.Nuclear shield: a multi-enzyme task-force for nucleus protectionMisfolded polypeptides are selectively recognized and transported toward aggresomes by a CED complexProtein quality control during erythropoiesis and hemoglobin synthesisAggresome-Autophagy Involvement in a Sarcopenic Patient with Rigid Spine Syndrome and a p.C150R Mutation in FHL1 GeneAmphetamine toxicities: classical and emerging mechanisms.Bim links ER stress and apoptosis in cells expressing mutant SOD1 associated with amyotrophic lateral sclerosis.Polyglutamine toxicity is controlled by prion composition and gene dosage in yeast.Protein aggregation and degradation mechanisms in neurodegenerative diseasesRole of ubiquitin-proteasome-mediated proteolysis in nervous system disease.Ubiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells.Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord.Mutations associated with Charcot-Marie-Tooth disease cause SIMPLE protein mislocalization and degradation by the proteasome and aggresome-autophagy pathways.Protein aggregation of SERCA2 mutants associated with Darier disease elicits ER stress and apoptosis in keratinocytes.Sarcoglycanopathies: molecular pathogenesis and therapeutic prospectsCigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration.Protein misfolding and clearance in demyelinating peripheral neuropathies: Therapeutic implications.
P2860
Q24314297-339CDE5A-5D68-498C-831A-6EE1FA424189Q24319015-7DB51FC5-6275-4328-B4D9-EA0AFAB744ADQ24608787-BD86DC54-7080-437E-B631-085BAE3448BAQ24629545-6EBC185B-2212-4015-98A8-478D343E5FDDQ24634983-6F5F2946-4548-4994-9FB5-469BFCEF9A2BQ26770342-52715963-1608-46DF-963D-4E54F3B3252DQ26799306-99A84ED4-FCDF-4393-B6D1-8AFF75C299ECQ26830475-ED92DFDA-995F-4CFF-9F95-B36732C560CCQ26998855-8D51C042-3E0F-403A-9F49-C581F9AF4114Q27021668-3BE58942-42DA-472F-A9BE-B15384FC10DCQ27312434-DCD5125D-12A2-4512-BD63-91AEA42DD6DEQ27675460-019A88E8-E61B-4CA7-B511-132BC946C3B7Q28386906-123D47BD-C6E6-49C2-9184-83211084FF2DQ28575023-0ADC7061-287C-439E-8E13-1A929BB37C77Q30356564-D1ED8FDF-6F84-4512-981C-92FFDDC8C004Q30372332-E1631641-CDA8-419D-8AFF-B4A0D396A4A9Q30479870-04F2BC4C-EFCF-4364-993D-989F4BCFD5EFQ30502900-F114186A-001A-4EBD-992C-374CD219C844Q30576520-86E54D71-15BC-4778-AC34-E74BDE3A9FFDQ30994681-EDDEAFB2-5903-453A-9880-8A868640928CQ33705006-743877BF-B7C7-49C3-BD22-4A88F6F54A74Q33745135-26DF837E-FF6D-4D0E-9F93-9769046965C5Q33757230-D078CFBD-AEDA-435A-A3A3-5209788ABEF9Q33757729-D86DB7B5-102B-430F-BB3B-80D2578A00F4Q33775554-E084087B-9F62-48ED-8007-D19EAE68DD5BQ33786504-43BE2207-091B-4FC7-8A70-A55AA9A894A4Q34060218-43BC46CC-C624-4990-A468-6224A2DBF0DCQ34063352-ED94E1F7-2480-4267-A343-E15AC5441CBBQ34102002-386EC6FD-CC1F-4DDD-986F-D9B3EFBDB662Q34241864-BA05A31F-32F2-4195-A772-D547DA3E69FEQ34246922-4F2CBC4F-ECE9-4079-ACAD-F83500DAAACCQ34334363-68947384-6B04-4669-9F7E-2B348E4D6A17Q34372681-719D076D-6D58-4D67-A600-38508FAF4927Q34381561-041625D8-DB97-44F1-9E85-9D7425511537Q35061120-89AD87BF-604B-483B-A7AB-CBF12EA23E1FQ35227491-1F39C9AE-F7EC-42B5-AD71-E0CD7A526E05Q35548395-43FD2C0D-3952-457C-AE7B-AD84E3DF3C28Q35758335-ADC1548D-52C7-4451-8C5B-F6C4BFC355CFQ35790324-3F4B9FF6-C3A3-4FDB-B0E8-68E527E75190Q35793427-AFAD1CD4-68CA-4088-84B3-79AB5BFE2DD7
P2860
Aggresome formation and neurodegenerative diseases: therapeutic implications
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Aggresome formation and neurodegenerative diseases: therapeutic implications
@ast
Aggresome formation and neurodegenerative diseases: therapeutic implications
@en
Aggresome formation and neurodegenerative diseases: therapeutic implications
@nl
type
label
Aggresome formation and neurodegenerative diseases: therapeutic implications
@ast
Aggresome formation and neurodegenerative diseases: therapeutic implications
@en
Aggresome formation and neurodegenerative diseases: therapeutic implications
@nl
prefLabel
Aggresome formation and neurodegenerative diseases: therapeutic implications
@ast
Aggresome formation and neurodegenerative diseases: therapeutic implications
@en
Aggresome formation and neurodegenerative diseases: therapeutic implications
@nl
P2860
P50
P3181
P1476
Aggresome formation and neurodegenerative diseases: therapeutic implications
@en
P2093
P2860
P3181
P356
10.2174/092986708783330692
P407
P577
2008-01-01T00:00:00Z